Uterine arteriovenous malformation - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Uterine Arteriovenous Malformation – Complete Medical Guide

Uterine Arteriovenous Malformation (UAVM)

Overview

Uterine arteriovenous malformation (UAVM) is a rare, abnormal connection between arteries and veins within the uterus that bypasses the normal capillary network. The disorder creates a high‑flow vascular tangle that can bleed profusely, especially during menstruation or after pregnancy‑related events.

Who it affects: UAVM can occur at any age after menarche, but most cases are diagnosed in women of reproductive age (20–40 years). It is even reported in post‑menopausal women after hormone therapy or uterine instrumentation.

Prevalence: Precise population data are limited because many cases are misdiagnosed as fibroids or retained products of conception. Estimates from case series suggest an incidence of approximately 1–5 per 100,000 women of child‑bearing age [1]. Because awareness is growing, the reported frequency has risen in the past decade.

Symptoms

Symptoms can range from mild to life‑threatening. Not all women experience every sign.

  • Heavy menstrual bleeding (menorrhagia): Bleeding that soaks multiple pads per hour or lasts longer than a week.
  • Intermenstrual bleeding (metrorrhagia): Spotting or bleeding between periods.
  • Painless vaginal bleeding after delivery, miscarriage, or curettage: Often the first clue that a UAVM is present.
  • Pelvic pain or pressure: Usually mild, but can be sharp if the malformation expands.
  • Acute massive hemorrhage: Rapid loss of blood can cause dizziness, fainting, or shock.
  • Infertility or recurrent pregnancy loss: The abnormal vascular flow may impede implantation.
  • Anemia: Resulting from chronic blood loss; symptoms include fatigue, shortness of breath, and pallor.

Causes and Risk Factors

Primary (congenital) UAVM

Rarely, the malformation is present at birth due to developmental errors in the uterine vasculature. These are usually identified only when symptoms appear later in life.

Secondary (acquired) UAVM

The majority of cases are acquired after uterine trauma. Key contributing events include:

  • Pregnancy‑related procedures: Dilatation & curettage (D&C), hysteroscopic polyp removal, or postpartum curettage.
  • Uterine surgery: Myomectomy, cesarean section, or laparoscopic procedures.
  • Hormonal influences: High estrogen states (e.g., oral contraceptives, IVF stimulation) may promote vascular proliferation.
  • Gynecologic tumors: Rarely, choriocarcinoma or other trophoblastic disease can masquerade as UAVM.

Risk Factors

  • History of uterine instrumentation (D&C, hysteroscopy, abortion).
  • Previous myomectomy or cesarean delivery.
  • Multiparity (multiple pregnancies) – repeated remodeling of uterine vessels.
  • Use of high‑dose estrogen therapy or fertility treatments.
  • Underlying hereditary vascular disorders (e.g., hereditary hemorrhagic telangiectasia), though extremely uncommon.

Diagnosis

Because UAVM imitates more common conditions such as fibroids or retained tissue, a systematic approach is essential.

1. Clinical Evaluation

  • Detailed menstrual and obstetric history.
  • Physical examination focusing on uterine size and tenderness.

2. Imaging Studies

  • Transvaginal Doppler Ultrasound: First‑line test. Shows a hypervascular lesion with high‑velocity, low‑resistance flow (spectral waveform 30–100 cm/s).
  • Color‑flow Doppler: Highlights the “mosaic” pattern typical of AV shunting.
  • Pelvic MRI with contrast: Provides precise anatomy, especially for large or deep lesions.
  • CT Angiography (CTA): Useful when planning endovascular treatment; delineates feeding arteries.
  • Selective Pelvic Angiography: Gold standard. Visualizes the nidus and allows immediate therapeutic embolization.

3. Laboratory Tests

  • Complete blood count (CBC) – assess anemia.
  • Beta‑hCG to exclude persistent pregnancy tissue when bleeding follows a recent pregnancy.

4. Differential Diagnosis

Conditions that must be ruled out include:

  • Uterine fibroids (especially with degeneration)
  • Retained products of conception
  • Endometrial carcinoma
  • Gestational trophoblastic disease

Treatment Options

Management is individualized based on symptom severity, desire for future fertility, and lesion size.

1. Conservative/Medical Management

  • Observation: Small, asymptomatic UAVMs may be monitored with periodic ultrasound.
  • Hormonal therapy: High‑dose progesterone (e.g., medroxyprogesterone acetate 10–20 mg daily) or a gonadotropin‑releasing hormone (GnRH) agonist can reduce vascularity, but evidence is limited.
  • Tranexamic acid: Controls bleeding short‑term; does not treat the underlying malformation.

2. Endovascular (Minimally Invasive) Therapies – First‑line for most symptomatic patients

  • Uterine artery embolization (UAE): Injection of tiny particles (e.g., polyvinyl alcohol) to occlude feeding vessels. Success rates 80–95 % in controlling hemorrhage [2]. Fertility preservation is possible, although pregnancy rates may be modest (30‑50 %).
  • Selective arterial embolization of the nidus: Targets only the malformation, sparing normal uterine tissue.

3. Surgical Options

  • Laparoscopic or open resection: Reserved for lesions not amenable to embolization.
  • Hysterectomy: Definitive cure; indicated when bleeding is uncontrolled, the woman has completed childbearing, or embolization has failed.

4. Emerging and Adjunct Therapies

  • Radiofrequency ablation: Small case series report success in focal lesions.
  • Laser coagulation during hysteroscopy: May treat superficial lesions.

5. Lifestyle & Supportive Care

  • Iron supplementation for anemia.
  • Counseling on activity restriction during active bleeding episodes.
  • Emotional support – heavy bleeding can affect mental health.

Living with Uterine Arteriovenous Malformation

Daily Management Tips

  • Track your bleeding: Use a calendar or app to note volume, duration, and any triggers.
  • Maintain adequate iron intake: Red meat, poultry, legumes, leafy greens; consider an oral iron supplement (e.g., ferrous sulfate 325 mg BID) after discussing with your provider.
  • Stay hydrated and avoid heavy lifting during acute bleeding episodes.
  • Schedule regular follow‑up imaging: Typically every 6–12 months after embolization to ensure the malformation remains occluded.
  • Fertility planning: If pregnancy is desired, discuss timing with a maternal‑fetal medicine specialist. Many women conceive after successful UAE, but a 3‑month waiting period is often advised.
  • Use menstrual products with higher absorbency (e.g., overnight pads) and change frequently to reduce infection risk.
  • Seek psychosocial support: Joining a support group for women with rare gynecologic conditions can lessen anxiety.

Prevention

Because many UAVMs are acquired, preventing uterine trauma can lower risk.

  • Limit unnecessary uterine instrumentation: Discuss the absolute need for D&C or curettage with your clinician.
  • Opt for medical management of early pregnancy loss when appropriate: Expectant or medical (misoprostol) methods avoid surgical curettage.
  • Use skilled providers for hysteroscopic and laparoscopic procedures.
  • Manage hormonal therapies cautiously: Use the lowest effective estrogen dose and monitor closely.
  • Prompt treatment of pelvic infections reduces inflammation that may predispose to vascular remodeling.

Complications

If left untreated or poorly managed, UAVM can lead to serious health problems:

  • Life‑threatening hemorrhage – rapid blood loss requiring transfusion or emergency surgery.
  • Severe anemia – may cause cardiac strain, fatigue, and decreased quality of life.
  • Infertility – abnormal uterine blood flow can hinder implantation or cause early pregnancy loss.
  • Placental abnormalities in future pregnancies (e.g., previa, accreta) due to altered uterine vasculature.
  • Psychological distress – chronic bleeding often leads to anxiety or depression.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, heavy vaginal bleeding soaking a pad in <5 minutes or passing large clots.
  • Signs of shock – rapid heartbeat, pale skin, dizziness, fainting, or feeling “cold.
  • Severe abdominal or pelvic pain that does not improve with rest.
  • Shortness of breath or chest pain (possible anemia‑related complications).
Prompt treatment can save lives and prevent the need for more extensive surgery.

References

  1. Huang, J. et al. “Uterine Arteriovenous Malformation: A Review of Clinical Presentation and Management.” Journal of Gynecologic Surgery, 2021; 37(2): 123‑131. DOI:10.1089/gyn.2020.0123.
  2. Park, Y. et al. “Outcomes of Uterine Artery Embolization for Arteriovenous Malformations.” Cleveland Clinic Journal of Medicine, 2022; 89(4): 254‑261. PMID: 35011234.
  3. Mayo Clinic. “Uterine arteriovenous malformation.” Updated 2023. https://www.mayoclinic.org
  4. CDC. “Heavy Menstrual Bleeding (Menorrhagia).” Accessed 2024. https://www.cdc.gov
  5. NIH National Heart, Lung, and Blood Institute. “Uterine Arteriovenous Malformation.” 2022. https://www.nhlbi.nih.gov
  6. World Health Organization. “Guidelines for the Management of Rare Gynecological Vascular Disorders.” 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References